Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes

Baricitinib is a Janus kinase (JAK) 1 and 2 inhibitor approved for treating rheumatoid arthritis (RA). The JAK/STAT system is essential in the intracellular signaling of different cytokines and in the activation process of the monocyte lineage. This study verifies the effects of baricitinib on STAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucci, Gloria, Garufi, Cristina, Pacella, Ilenia, Zagaglioni, Marta, Pinzon Grimaldos, Alessandra, Ceccarelli, Fulvia, Conti, Fabrizio, Spinelli, Francesca Romana, Piconese, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357974/
https://www.ncbi.nlm.nih.gov/pubmed/35958600
http://dx.doi.org/10.3389/fimmu.2022.932240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357974/
https://www.ncbi.nlm.nih.gov/pubmed/35958600
http://dx.doi.org/10.3389/fimmu.2022.932240

Ejemplares similares